FDA Grants Accelerated Approval to Epkinly for Relapsed or Refractory Follicular Lymphoma

The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab U.S.), a bispecific CD20-directed CD3 ...

JUNE 27, 2024